RU58841

A topical-only, non-steroidal androgen receptor antagonist designed in the 1980s-90s by Roussel-Uclaf for prostate cancer, shelved before approval, and resurrected by the hair-loss community as a "PFS-free" alternative to finasteride/dutasteride. Mechanism is real and elegant — block AR locally at scalp follicles, deactivate quickly so nothing reaches the rest of the body. For Dylan at 20 with no MPB, this is treatment for a problem he doesn't have. Skip until needed; when needed, the more interesting question is whether to start with finasteride/dutasteride (massive RCT base) or RU58841 (mechanistic appeal, sourcing risk, sparse human safety data).

RU58841 is a non-steroidal anilide-class AR antagonist developed by Roussel-Uclaf (the original maker of mifepristone / RU-486) in the late 1980s. Chemically it is closely related to nilutamide and flutamide — first-generation non-steroidal anti-androgens used systemically in metastatic prostate cancer — but designed with a specific local-use profile.

Local AR blockade at hair follicles:

1. Androgenetic alopecia is driven by DHT binding the AR in genetically susceptible dermal papilla cells of scalp follicles → triggers miniaturization (anagen shortening, follicle thinning, eventual exhaustion).
2. RU58841 applied topically penetrates the scalp epidermis into the dermal papilla.
3. It competitively binds the AR with affinity comparable to or exceeding DHT itself, displacing DHT from the receptor without activating it.
4. Without AR signaling, the miniaturization signal is interrupted — surviving follicles regrow toward terminal hair, and not-yet-miniaturized follicles are protected.
5. Crucially, this is receptor-blockade downstream of where finasteride and dutasteride act (5α-reductase, the DHT-synthesizing enzyme). RU58841 does not affect circulating DHT levels at all when working as designed — it just denies DHT access to the receptor in the target tissue.

Why "topical-only" was the design goal:

• The pharmacological precedent (flutamide, nilutamide, bicalutamide) showed systemic AR antagonism causes gynecomastia, libido loss, mood and energy changes, hot flushes, fatigue, and hepatotoxicity. These are expected consequences of blocking AR signaling everywhere.
• Roussel-Uclaf engineered RU58841 to be rapidly metabolized to inactive forms once it enters systemic circulation — the molecule has features (ester groups, lability) that make it a relatively poor systemic agent compared to bicalutamide. This was intentional: confine activity to the application site.
• In animal scalp models the design works well; the unresolved question is exactly how completely systemic deactivation occurs in real-world humans, especially with daily long-term use, larger application areas, damaged scalp barrier, occluded delivery, or DMSO/ethanol vehicles that increase absorption.

Pharmacokinetics (what's known and what isn't):

• Topical scalp half-life: ~2-3 hours at the application site, but practical "duration of useful blockade" appears longer because AR turnover is slow.
• Systemic half-life if any escapes deactivation: poorly characterized in humans; in the rat model, plasma levels were low but detectable at higher doses.
• No clinical pharmacokinetic dataset in humans at hair-loss doses (5% solution, 1-2 mL/day) with modern bioanalytical sensitivity. This is one of the largest unknowns.
• Vehicle matters substantially — ethanol/PG vehicles, DMSO-containing vehicles, and "Kirkland-style" minoxidil-like solutions all change absorption kinetics. Absorption is higher with damaged or inflamed scalp.

What RU58841 is NOT doing:

• Not blocking 5α-reductase (finasteride/dutasteride do that — RU58841 leaves circulating DHT alone).
• Not lowering testosterone (no HPG-axis effect at design intent).
• Not affecting estradiol synthesis.
• Not stimulating hair growth like minoxidil (which is a vasodilator / K+-channel opener with a different mechanism — RU58841 protects existing follicles from miniaturization, minoxidil prolongs anagen and increases follicle size).
• Not a steroid — the "anti-androgen" label is functional, not structural.